Results 61 to 70 of about 9,702 (191)

CRISPR-Cas9 Screening of Kaposi’s Sarcoma-Associated Herpesvirus-Transformed Cells Identifies XPO1 as a Vulnerable Target of Cancer Cells

mBio, 2019
The abnormal proliferation of cancer cells is driven by deregulated oncogenes or tumor suppressors, among which the cancer-vulnerable genes are attractive therapeutic targets.
Marion Gruffaz, Hongfeng Yuan, Wen Meng, Hui Liu, Sangsu Bae, Jin-Soo Kim, Chun Lu, Yufei Huang, Shou-Jiang Gao   +8 more
doaj   +1 more source

Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication

Scientific Reports, 2021
Respiratory syncytial virus (RSV) is the primary cause of serious lower respiratory tract disease in infants, young children, the elderly and immunocompromised individuals.
Cynthia Mathew, Sharon Tamir, Ralph A. Tripp, Reena Ghildyal   +3 more
doaj   +1 more source

Selinexor and COVID-19: The Neglected Warden

Frontiers in Pharmacology, 2022
A novel severe acute respiratory distress syndrome coronavirus type 2 (SARS-CoV-2) has been confirmed as the cause of the global pandemic coronavirus disease 2019 (COVID-19).
Gomaa Mostafa-Hedeab, Gomaa Mostafa-Hedeab, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nermeen N. Welson, Gaber El-Saber Batiha, Carlos Adam Conte-Junior   +6 more
doaj   +1 more source

Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature [PDF]

, 2018
Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma that is treated with first-line therapy, using surgical resection followed by local radiotherapy and concomitant/adjuvant temozolomide (TMZ) treatment.
Berrios J. R. G., Bianco V., Caffarena G., Caporlingua A., Caporlingua F., Di Palma A., Fusto C., Magliocca F. M., Pecorari S., Prelaj A., Rebuzzi S. E., Salvati M., Tomao S.   +12 more
core   +1 more source

Exportin 1 Inhibitor Combined With Venetoclax Induces Apoptosis in Myelodysplastic Syndrome by Mitochondria‐Induced Apoptosis Pathway

Journal of Clinical Laboratory Analysis, EarlyView.
Inhibition of XPO1 is a promising modality in the treatment of MDS, especially when combined with Venetoclax, which activates mitochondria‐mediated apoptosis and could be a potential target for MDS therapy. ABSTRACT Background Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies that pose a serious health threat.
Xiaohan Liu, Lei Huang, Junzhu Wang, Yixuan Guo, Hongli Shen, Xianghong Zhao, Lanzhu Yue, Zhaoyun Liu, Rong Fu   +8 more
wiley   +1 more source

MiR‐483‐3p improves learning and memory abilities via XPO1 in Alzheimer's disease

Brain and Behavior, 2022
Introduction Alzheimer's disease (AD), a common form of dementia, has been reported to influence 27 million individuals globally. Several risk factors including oxidative stress, gut microbiota imbalance, and cognitive activity are reported to be closely
Gang Luo, Xiaoyan Wang, Changya Liu
doaj   +1 more source

Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors

Cancer Research, 2017
Exportin 1 (XPO1) mediates nuclear export of many cellular factors known to play critical roles in malignant processes, and selinexor (KPT-330) is the first XPO1-selective inhibitor of nuclear export compound in advanced clinical development phase for cancer treatment.
Fabio, Conforti, Xu, Zhang, Guanhua, Rao, Tommaso, De Pas, Yoko, Yonemori, Jose Antonio, Rodriguez, Justine N, McCutcheon, Raneen, Rahhal, Anna T, Alberobello, Yisong, Wang, Yu-Wen, Zhang, Udayan, Guha, Giuseppe, Giaccone   +12 more
openaire   +3 more sources

CRISPR‐Cas9 Genome‐Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies

Medicinal Research Reviews, EarlyView.
ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He, Patrick Connerty, Antoine de Weck   +2 more
wiley   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

British Journal of Haematology, EarlyView.
A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide‐refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose ...
Sosana Delimpasi, Ivan Špička, Jason P. Butler, Don A. Stevens, Mercedes Gironella Mesa, Ceri Bygrave, Giovanni Marino Merlo, Charles la Porte, Meletios A. Dimopoulos   +8 more
wiley   +1 more source